Michele Orditura
Overview
Explore the profile of Michele Orditura including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
124
Citations
2724
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Grisolia P, Tufano R, Iannarone C, De Falco A, Carlino F, Graziano C, et al.
J Transl Med
. 2024 Oct;
22(1):938.
PMID: 39407254
Background: Recent studies have highlighted the importance of the cell-free DNA (cfDNA) methylation profile in detecting breast cancer (BC) and its different subtypes. We investigated whether plasma cfDNA methylation, using...
2.
Caminiti C, Maglietta G, Arenare L, Di Liello R, Migliaccio G, Barberio D, et al.
Breast
. 2024 Jul;
77:103781.
PMID: 39059033
Patients' self-reporting is increasingly considered essential to measure quality-of-life and treatment-related side-effects. However, if multiple patient-reported instruments are used, redundancy may represent an overload for patients. Patient-Reported Outcomes Common Terminology...
3.
Orlando L, Maiello E, Orditura M, Diana A, Antoniol G, Morritti M, et al.
Breast
. 2024 Apr;
75:103725.
PMID: 38615483
Background: Optimizing chemotherapy to achieve disease and symptoms control is a noteworthy purpose in advanced breast cancer (ABC). We reported the activity and quality of life of a phase II...
4.
Carlino F, Solinas C, Orditura M, Bisceglia M, Pellegrino B, Diana A
Front Oncol
. 2024 Mar;
14:1321654.
PMID: 38469228
No abstract available.
5.
Parisi S, Gambardella C, Iovino F, Ruggiero R, Lucido F, Nesta G, et al.
J Clin Med
. 2024 Jan;
13(2).
PMID: 38256700
Breast angiosarcoma is a rare malignancy, accounting for less than 1% of all soft tissue cancers. It comprises primitive and secondary subtypes, such as radiogenic breast angiosarcoma (RAS). Despite multimodal...
6.
Morgillo F, DAiuto E, Troiani T, Martinelli E, Cascone T, De Palma R, et al.
Lung Cancer
. 2023 May;
181:107226.
PMID: 37167905
No abstract available.
7.
Marino F, Buono S, Montella M, Giannatiempo R, Messina F, Casaretta G, et al.
J Pathol Clin Res
. 2023 May;
9(5):367-377.
PMID: 37143440
Triple-negative breast cancer (TNBC) is usually an aggressive disease with a poor prognosis and limited treatment options. The neurotrophic tyrosine receptor kinase (NTRK) gene fusions are cancer type-agnostic emerging biomarkers...
8.
Malorni L, Bianchini G, Caputo R, Zambelli A, Puglisi F, Bianchi G, et al.
Eur J Cancer
. 2023 Apr;
186:1-11.
PMID: 37003098
Background: Thymidine kinase 1 (TK1) is an enzyme downstream of the CDK4/6 pathway, with a critical role in DNA synthesis; serum TK1 activity (sTKa) is a novel liquid biopsy biomarker...
9.
Zannini G, Facchini G, De Sio M, De Vita F, Ronchi A, Orditura M, et al.
Pathol Res Pract
. 2023 Feb;
243:154336.
PMID: 36736144
BRCA1 and BRCA2 are onco-suppressor genes involved in the DNA repair mechanism. The presence of BRCA1/2 mutations confers a higher risk of developing several cancer types. To date, the FDA...
10.
Iovino F, Diana A, Carlino F, Ferraraccio F, Antoniol G, Fisone F, et al.
J Clin Med
. 2022 Dec;
11(23).
PMID: 36498560
Introduction: The mesenchymal-epithelial transition factor (c-MET) receptor is overexpressed in about 14−54% of invasive breast cancers, but its prognostic value in clinical practice is still unclear. Methods: In order to...